8
total announcements
SENORES.NS · 15 min delayed
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has scheduled an earnings conference call for Q1FY27 on July 27, 2026, following the announcement of unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has submitted the Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026, as per SEBI (Depositories and Participants) Regulations, 2018.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, confirming the acceptance or rejection of dematerialized securities and listing of securities on stock exchanges.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the completion of dispatch of Notice of Postal Ballot, intimation of e-voting and other related information.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding a Postal Ballot Notice for seeking approval of shareholders on several items of Special Business, including related party transactions and loan/guarantee enhancements.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange about a scheduled meeting with analysts and institutional investors at its plant in Chhatral, Gujarat, and corporate office in Ahmedabad, Gujarat, on July 7, 2026.
Senores Pharmaceuticals Limited
The board of directors of Senores Pharmaceuticals Limited has approved a variation in the utilization of unutilized IPO proceeds to the extent of ₹ 1000.16 million, subject to shareholder approval through postal ballot.
Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of unaudited financial results for the quarter ending June 30, 2026.